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ABSTRACT – Background and Objectives: Studies have shown showed that delirium af-
fects the long-term functional status, however, the acute effect of delirium on functioning
has been less documented. The purpose of this analysis was to examine the acute impact
of delirium on the level of functioning.
Methods: All patients were recruited at the Memorial Sloan Kettering Cancer Center
(MSKCC). The Memorial Delirium Assessment Scale (MDAS) and Karnofsky scale of
Performance Status (KPS) were recorded at baseline (T1), 2-3 days (T2) and 4-7 days
(T3). A secondary analysis in respect to sociodemographic and medical variables, aspects
of delirium, and level of functioning was performed.
Results: Delirium severity at baseline did not affect the level of functioning, however, re-
solved delirium resulted in substantial functional recovery compared to persistent delirium
at T2 (30.2 and 23.5) and T3 (35.1 and 26.2). Patients with persistent functional impairment
were not different in age, pre-existing dementia or brain metastasis compared to those with
functional recovery. However, brain cancer, terminal illness, hypoxia and multiple etiolo-
gies caused persistent functional decline. Although delirium severity was not different at
baseline, delirium was more severe in the functionally-impaired at T2 and T3. Similarly,
delirium resolution was inferior in these patients in contrast to the functionally-recovered at
T2 (25% and 65.4%) and T3 (62.5% and 83.3%). On the contrary, the duration of delirium
affected functional recovery; shorter delirium predicted faster functional recovery.
Conclusions: Delirium caused an acute functional decline and appropriate management of
delirium with antipsychotics reversed this decline. On the contrary, shorter duration of deliri-
um was associated with faster functional recovery. Brain cancer, terminal illness, hypoxia,
and multiple etiologies were confounders for persistent delirium and functional impairment.
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Background
Delirium is associated with poor functional
outcome, increased morbidity and mortality,
as well as prolonged hospitalization1, and is
a common event in the course of hospital-
ization depending on the age of the patient
and the severity of the illness2,3. In the gen-
eral hospital setting, 14-24% of older pa-
tients present with delirium on admission,
and 6-56% will develop delirium during the
course of hospitalization4. In this setting, the
occurrence of delirium is high and varies in
medically ill patients between 15-30%, in
the hospitalized elderly between 10-40%4,5,
in cancer patients between 57-85%, and in
terminal illness, the incidence of delirium
can reach up to 85%6-8.
Several studies have indicated that the inci-
dence of delirium prolongs hospitalization and
that in particular in older patients, delirium has
an impact on the cognitive and functional sta-
tus with or without dementia9-11. In addition,
delirium has been shown to lead to an acute
decline in functional status12, to be one of the
most common reasons for admission to the
hospital in patients with advanced cancer and
to herald an even greater decline in perfor-
mance13. In fact, the effect on the functional
status is prominent. The impairment in the
level of functioning may last up to 12 months9-
11
, thus representing a challenge in the process
of recovery for the elderly and demented. Fur-
ther, an association between the length of per-
sistence of delirium symptoms and functional
recovery has been documented. The persis-
tence of delirium symptoms for less than two
weeks was associated with excellent func-
tional recovery, whereas persistence for a
longer time was associated with less favorable
outcomes14. Even more, delirium predicted
greater mortality and accelerated cognitive
decline in dementia15-17.
The current literature suggests that delir-
ium has an impact on the functional status.
Most studies focused on the long-term effect
on the functional status, whereas results doc-
umenting the acute impact of delirium re-
main scarce. In order to further explore the
impact of delirium on functioning, an analy-
sis in respect to the level of functioning, con-
tributing etiological factors and delirium res-
olution was performed.
Methods
Patients
All patients were recruited from patients
referred for delirium management to the
Memorial Sloan Kettering Cancer Center
(MSKCC) Psychiatry Service from July to
November 2000 and from July 2004 to June
2006. MSKCC is a 452 bed private hospital
specializing in the treatment of cancer, aver-
aging more than 20,000 admissions every
year. The Consultation-Liaison Psychiatry
Service performs on average more than 2,000
consultations yearly.
The main inclusion criterion was meeting
the DSM-IV-TR18 criteria for delirium. Ex-
clusion criteria included patient or family ob-
jections to pharmacologic intervention, in-
ability to participate with delirium rating, and
severe agitation interfering with the interview.
All patients and their families provided
verbal consent to be evaluated and receive an-
tipsychotics for symptomatic relief of delir-
ium. In patients with limited capacity to pro-
vide consent, the patient’s primary caregiver
provided verbal consent alongside the pa-
tient’s assent to intervention. When patients
or families were not willing to be evaluated
or did not agree to management with an-
tipsychotics, their data was not recorded. All
data was obtained from the routine daily clin-
ical care of patients diagnosed with delirium
documenting the course of delirium, entered
into the IRB-approved-database for subse-
quent analysis and was a waiver obtained for
the analysis.
Measurements
Delirium severity was measured with the
MDAS20, a 10-item, four-point clinician-rated
scale (possible range 0-30)20. Scale items as-
sess the disturbance in arousal and level of
consciousness, as well as several areas of
cognitive functioning, psychomotor activity,
and sleep-wake cycle. An MDAS score of
>10 identifies the presence of delirium21,22.
Delirium severity is categorized by using the
MDAS scores as follows: mild delirium
(MDAS<16), moderate delirium (MDAS 16-
22) and severe delirium (MDAS>22). The
MDAS uses psychomotor behavior for the
subtypes of delirium and was based on the
predominant presentation, hypoactive or hy-
peractive psychomotor behavior.
The level of functioning was assessed with
the Karnofsky scale of Performance Status
(KPS), indicating physical performance abil-
ity19. The KPS has been validated for the
functional assessment of cancer patients and
ranges from 10-100. In particular, scores of
less than 50 indicate an inability to care for
oneself and therefore require hospital care. A
score of 40 indicates disability with the need
for assistance and a score of 30 indicates se-
vere disability and indicates the need for hos-
pital admission. A score of 20 indicates the
necessity of hospital admission in a very sick
patient requiring active treatment and a score
of 10 indicates being moribund.
MDAS and KPS rating were performed by
the fellows of the consultation-liaison psychi-
atry service who were trained by William Bre-
itbart20 who established the MDAS. Inter-rater
reliability was performed between fellows,
however, not formally evaluated as the purpose
of the database was the documentation of clin-
ical routine and the course of delirium.
Procedures
Sociodemographic and medical variables,
such as age, sex, cancer diagnosis, stage of
can cer (localized, metastatic, or terminal),
psychiatric diagnosis including pre-existing
dementia, presence of brain metastases, and
delirium etiologies were collected at the base-
line assessment. Antipsychotic medication
was initiated upon diagnosis of delirium and
adjusted as determined by clinical response.
In accordance with the guidelines for the
treatment of delirium23, the standard approach
was to manage delirium with antipsychotics
and continue the necessary medical treatment,
including risk factors for delirium such as the
administration of opiates or corticosteroids,
and to treat reversible underlying causes such
as hypoxia and infection.
MDAS, KPS and side effect rating were
performed at baseline (T1), repeated at 2-3
days (T2) and 4-7 days (T3), Rating was per-
formed once on the indicated days, usually in
the early afternoon. After seven days, the ob-
servation period ended. Patients were contin-
ued on antipsychotic medication as necessary.
Statistical Analysis
Data analyses were performed with the
Statistical Package for the Social Sciences
(SPSS) 20 for Windows. The primary inter-
ests were resolved and persistent delirium.
The secondary interests were functional re-
covery versus functional impairment, in ad-
dition to sociodemographic and medical vari-
ables, as well as delirium severity.
88 SUSANNE BOETTGER ET AL.
In a first step, the dataset was defined as a
dichotomous variable with two levels: Re-
solved delirium and persistent delirium. The
dichotomous set was analyzed in respect to
the level of functioning (KPS). In a second
step, medical variables that were associated
with an improvement in the level of func-
tioning of less than 10 on the KPS represent-
ing patients with functional impairment were
identified and then defined as a dichotomous
variable accordingly. The comparison group
was defined as patients with KPS improve-
ment of more than 10 representing functional
recovery. In the functionally-impaired, KPS
scores were 22.7 (10-30, SD 5.4) at baseline
and, 22.1 (10-30 SD 5.8) at T3. In the func-
tionally-recovered, KPS scores were 25.1 (20-
40, SD 5.9) and 41.3 (30-70, SD 10.6), re-
spectively. At T3, the level of functioning was
superior in the functionally-recovered (t-test:
t = -11.4(109), p<0.001).
The t-test for independent variables was
computed for continuous variables, such as
the age of patients, medication dosing, MDAS
and KPS scores between subsets and the one-
way ANOVA for multiple, independent mea-
sures such as the description of the level of
functioning in mild, moderate and severe
delirium. The ANOVA repeated measures test
was used for repeated measures of dependent
variables, such as subsequent MDAS and
KPS scores. Pearson’s Chi-square test was
used for categorical variables such as the
prevalence of terminal illness in haloperidol-
managed patients. In order to analyze the ef-
fect of medical variables on functional im-
pairment and recovery, multivariate logistic
regression analyses were performed.
The significance level alpha (α) was set at
p<0.05.
Results
Baseline characteristics
Overall, 111 cases of delirium managed
with haloperidol, risperidone, olanzapine and
aripiprazole for delirium were retrieved. The
patients had an advanced age, were predomi-
nantly male, and hypoactive delirium and hy-
peractive delirium were equally distributed.
Cancer diagnoses were diverse and delirium
was generally multifactorial (table 1).
Description of the level
of functioning
The functional status was impaired at base-
line and improved throughout the manage-
ment period. KPS scores increased from 24.1
at baseline, to 28.6 at T2 and to 33.0 at T3
(ANOVA: F = 80.5, p<0.001). Surprisingly,
delirium severity as measured by mild, mod-
erate and severe delirium did not influence the
level of functioning (ANOVA: F = 1.60, p =
0.207). At baseline, KPS scores in mild delir-
ium were 25.5 (10-40, SD 7.2), in moderate
delirium 23.2 (20-40, SD 5.1) and severe
delirium 24.2 (20-30, SD 5.1). Instead, there
were differences in respect to the resolution of
delirium: In patients with resolved delirium,
KPS scores increased from 24.4 (20-40, SD
5.7) at baseline to 30.2 (20-60, SD 10.9) at T2
and 35.1 (10-70, SD 13.2) at T3 (ANOVA: F
= 82.2, p<0.001). In patients with persistent
delirium, an improvement in KPS scores was
noted, but to a lesser amount. KPS scores in-
creased from 23.1 (10-30, SD 6.2) at baseline
to 23.5 (10-30, SD 6.9) at T2 and 26.2 (10-40,
SD 9.4) at T3 (ANOVA: F = 6.5, p = 0.018).
Between patients with resolved and persistent
delirium, KPS scores were not different at
baseline, however, at T2 and T3, KPS scores
and thus the level of functioning were higher
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Table 1
Sociodemographic and medical characteristics of patients with functional impairment and functional recovery
All patients Functional impairment Functional recovery
(N = 111) (N = 48) (N = 63)
Age 65.6 (23-89, SD 13.7) 66.4 (29-89, SD 13.0) 64.9 (23-85, SD 14.2)
Gender in %
Male 41.4 58.3 58.7
Female 58.6 41.7 41.3
Dementia in % 19.8 22.9 17.5
Diagnoses in %
Lung 21.6 22.9 20.6
Brain 10.8 16.7 6.3
Gastrointestinal 23.4 22.9 23.8
Genitourinary 9 8.3 9.5
Sarcoma 7.2 4.2 9.5
Head and neck 6.3 6.3 6.3
Gynecological 9 6.3 11.1
Endocrine 2.7 – 4.8
Lymphoma 0.9 2.1 –
Skin 2.7 2.1 3.2
Hematological 1.8 2.1 1.6
Other 3.6 2.1 3.2
Stage in %
Localized 34.9 26.1 41.3
Advanced 47.7 45.7 49.2
Terminal 17.4 28.3 9.5
Brain metastases in % 9 7.9 10.4
Etiologies in %
Opioids 88.3 81.2 93.7
Corticosteroids 53.2 54.2 41.3
Infection 24.3 31.2 19
Hypoxia 36.9 50 27
CNS disease 12.6 27.1 12.7
Dehydration 5.4 4.2 6.3
Other medication 81.1 87.5 82.5
Other 84.7 83.3 79.4
Total number of etiologies 5 (3-8, SD 1) 5.3 (3-8, SD 1.9) 4.7 (3-7, SD 0.9)
SD (Standard Deviation).
in patients with resolved delirium indicating
functional recovery. At T2, KPS scores were
23.5 (10-30, SD 6.9) in persistent delirium
and 30.2 (20-60, SD 10.9) in resolved delir-
ium (t-test: t = -3(109), p = 0.004) and at T3,
KPS scores were 26.2 (10-40, SD 9.4) and
35.1 (10-70, SD 13.2) (t-test: t = -3.2(109), p
= 0.002), respectively.
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Table 2
Multivariate logistic regression analyses of medical variables
B (SE) Wald’s χ2 Significance Odds Ratio
Lung -4.53 (1.11) 0.17 0.684 –
Brain -2.62 (1.33) 3.86 0.050 0.07
Gastrointestinal -0.51 (1.12) 0.21 0.648 –
Genitourinary -0.28 (1.28) 0.05 0.827 –
Sarcoma -0.46 (1.40) 0 0.973 –
Head and neck -1.57 (1.40) 1.26 0.261 –
Gynecological 0.29 (1.25) 0.05 0.820 –
Skin -0.87 (1.68) 0.27 0.604 –
Hematological -0.24 (2.01) 0.01 0.788 –
Stage of illness -1.26 (0.41) 9.54 0.002 0.28
Opioids 1.31 (0.72) 3.37 0.066 –
Corticosteroids -0.59 (0.48) 1.50 0.221 –
Infection -0.86 (0.53) 2.70 0.100 –
Hypoxia -1.03 (0.48) 4.65 0.031 0.36
CNS disease -0.81 (0.79) 1.05 0.305 –
Dehydration 0.65 (1.18) 0.30 0.584 –
Other medication -0.38 (0.66) 0.33 0.567 –
Other -0.45 (0.63) 0.50 0.480 –
Delirium subtype 1.01 (0.66) 2.37 0.124 –
Delirium resolution at
T2 1.60 (0.78) 4.17 0.041 4.94
T3 1.94 (0.89) 4.76 0.029 6.95
χ2 (Chi-Square), SE (Standard Error).
Patients with functional
impairment
Patients with functional recovery or im-
pairment were not different in age, by pre-ex-
isting dementia, or brain metastases (table 1
and 3). There was a trend towards brain can-
cer (16.7% and 6.3%) contributing to func-
tional impairment and terminal cancer con-
tributed to functional impairment (28.3% and
9.5%). Among etiologies, only hypoxia (50%
and 27%) and multiple etiologies caused
more severe functional impairment (table 2).
There were also few differences in man-
agement characteristics (table 3). Hypoac-
tive and hyperactive delirium was similarly
distributed with 50% in the functionally-im-
paired compared to 41.3% and 58.7% in the
functionally-recovered. There were no dif-
ferences in respect to the dosing of risperi-
done, olanzapine or aripiprazole between the
functionally-impaired and -recovered. Only,
when haloperidol was administered higher
doses were given to the functionally-recov-
ered (2.9 mg and 6.2 mg). However, there
was also a trend towards the functionally-
impaired managed with haloperidol being
older (68.3, 42-86, SD 13.3 vs. 58.4, 23-78,
SD 13.9, t-test: t = 1.82(2), p = 0.078) and
suffering more often from terminal illness
(31.3% and 5.3%, χ2 (1) 4.13, p = 0.073).
Furthermore, there were no differences in
MDAS scores at baseline (18.2 and 18.3), at
T2 and T3 however, delirium was more se-
vere in the functionally-impaired. MDAS
scores at T2 were 13.1 and 8.9 and at T3
were 10.6 and 6.0 indicating the functionally-
impaired did not achieve delirium resolution.
Although MDAS scores decreased in all pa-
tients, the delirium resolution was inferior
in the functionally-recovered: At T2, delirium
resolution was 63.5% and 25% and at T3,
87.3% and 62.5%, respectively. On the con-
trary, functional recovery was associated with
shorter delirium.
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Table 3
Delirium and management characteristics of patients with functional impairment and functional recovery
Functional impairment Functional recovery Statistics
(N = 48) (N = 63)
Age 66.4 (29-89, SD 13) 64.9 (23-85, SD 14.2) 0.56(109), p = 0.579 a
Total number of etiologies 5.3 (3-8, SD 1.9) 4.7 (3-7, SD 0.9) 3.05(109), p = 0.003 a
MDAS
Baseline 18.2 (11-30, SD 5) 18.3, 11-29, SD 4.3 -0.08(109), p = 0.935 a
T2 13.1 (4-25, SD 4.3) 8.9 (1-24, SD 4.7) 4.54(109), p<0.001 a
T3 10.6 (3-26, SD 5.6) 6.0 (1-17, SD 3.7) 5.18(109), p<0.001 a
Statistics F = 95.2, p<0.001 b F = 331.2, p<0.001 b
KPS
Baseline 22.7 (10-30, SD 5.4) 25.1 (20-40, SD 5.9) -2.18(109), p = 0.032 a
T2 22.3 (10-30, SD 5.6) 33.4 (20-60, SD 33.5) -6.55(109), p<0.001 a
T3 22.1 (10-30, SD 5.8) 41.3 (30-70, SD 10.5) -11.35(109), p<0.001 a
Statistics F = 1.8, p = 0.182 b F = 263.5, p<0.001 b
Medication at T3 in mg
Haloperidol 2.9 (1-6, SD 1.6) 6.2 (1.5-16, SD 3.6) -3.37(33), p = 0.002 a
Risperidone 1.3 (0.25-3, SD 0.8) 1.3 (0.5-3, SD 0.7) -.20(30), p = 0.841 a
Olanzapine 6.5.(2.5-15, SD 4.5) 5 (2.5-10, SD 2.2) 5.39(20), p = 0.363 a
Aripiprazole 22.5 (15-30, SD 6.1) 16.7 (10-30, SD 6.2) 1.96(19), p = 0.065 a
Memorial Delirium Assessment Scale (MDAS), Karnofsky Performance Status scale (KPS), SD (Standard De-
viation), a t-test, b ANOVA repeated measures test.
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Whereas the level of functioning expect-
edly improved in the functionally-recovered,
the functionally-impaired did not achieve im-
provement in KPS scores or the level of func-
tioning.
Discussion
These findings suggest that delirium had
an acute impact on the level of functioning in
the course of hospitalization and that active
management of delirium with antipsychotics
reversed this effect. On the contrary, shorter
delirium was associated with functional re-
covery. In this respect, these results con-
firmed previous findings which have shown
that delirium has an acute impact on the level
of functioning13, however, add new insights
into the necessity of active management with
antipsychotics in order to reverse this effect.
Furthermore, brain cancer, terminal illness,
hypoxia, and multiple etiologies were con-
founders for persistent delirium and func-
tional impairment.
It is known that delirium has a long-term
effect on cognitive and functional status in
older patients with or without dementia9-11.
Also, an interaction between the length of
persistence of delirium symptoms and func-
tional recovery has been documented: The
shorter the persistence of delirium symp-
toms, the better the functional recovery has
been. In particular, persistence of delirium for
less than two weeks has been associated with
excellent functional recovery14.
Similarly, within one week of observation,
the functional recovery was also superior
with a shorter duration of delirium as docu-
mented by the functionally-recovered in con-
trast to the functionally-impaired. Although
at baseline, no differences in delirium sever-
ity between the functionally-impaired and -
recovered existed, in the course of manage-
ment, more severe and persistent delirium
became apparent in the functionally-impaired
at T2 and T3. Thus, the necessity of actively
managing delirium in order to accelerate the
functional recovery process and prevent in-
creased morbidity, mortality and rates of in-
stitutionalization1 ought to be a primary goal
and while previously shown in the long-term
setting, extended to the acute care setting.
Surprisingly, the severity of delirium, mild,
moderate, or severe, did not affect the func-
tional status independently, interesting aspects
remain. Persistent delirium had an impact on
the functional status in the acute care setting
and, in contrast, the level of functioning im-
proved with delirium resolution. This indi-
cated that successful management of delirium
with antipsychotics caused the reversal of
functional impairment. This effect extended to
patients with persistent delirium in whom the
level of functioning also improved, however,
the improvement was less pronounced.
At baseline, there were no differences in
functional status between the functionally-
impaired and -recovered. Over the course of
management, the functional status of patients
with resolved delirium improved and was su-
perior to patients with persistent delirium.
Of interest, this effect appeared to affect all
patients with delirium in contrast to previous
studies that found persistent delirium in older
patients over several months. Still, patients
with persistent delirium and lower KPS
scores were older than patients with resolved
delirium (71.3 and 63.8 years), which implied
that advanced age could be associated with a
protracted and refractory course of delirium
and a more severe and prolonged impact on
the level of functioning.
As medical factors may contribute to func-
tional impairment, these variables were iden-
tified by examining cases with functional im-
pairment. There were no differences with re-
spect to age, pre-existing dementia, or brain
metastases, except for an increased prevalence
of brain cancer, terminal illness, hypoxia, and
multiple etiologies in the functionally-im-
paired. These factors were confounded per-
sistent delirium as has been previously
shown8,24,25.
With respect to the adequacy of manage-
ment, the dosing of antipsychotic medication
did not appear to have an effect on functional
improvement. When risperidone, olanzapine,
or aripiprazole were administered, no differ-
ences existed between the functionally-im-
paired and -recovered. Only in patients man-
aged with haloperidol higher doses were
administered to the functionally-recovered.
However, these patients tended to be older and
terminal illness was present at a higher rate,
which in part could have explained differ-
ences in haloperidol dosing. Overall, the med-
ication doses administered were comparable
to those in existing studies26.
There are a number of limitations to be
noted. Although the design of the data col-
lection was prospective, it was not possible to
follow patients prior to the onset of delirium
and measure the impact of delirium in a
prospective manner. Instead, the reversal of
impairment in the level of functioning was
described and deduced on the impact of delir-
ium on the level of functioning. Due to the
design of the data collection, measuring the
first MDAS upon presentation with delirium,
it was not possible to obtain a baseline cog-
nitive assessment of functional assessment.
Further, the observation period was limited to
one week and a longer observation period
would have been preferable. In addition,
there was a selection of patients with delirium
through the referral process, as well as an ex-
clusion of patients unable or unwilling to
comply with rating. Although all rater were
trained by the creator of the MDAS and inter-
rater reliability was performed, no formal
evaluation of the inter-rater reliability was
recorded. The delirium database contained
data of the management of delirium with
aripiprazole, haloperidol, risperidone, and
haloperidol. Delirium was classified as hy-
poactive and hyperactive by predominant pre-
sentation, the mixed subtype was not as-
signed. All patients were naturally assigned
to a medication, the assignment was not ran-
dom. All patients had cancer diagnoses and
the generalizability of results to the non-can-
cer population remains to be evaluated. The
use of antipsychotics in the management of
delirium has not been approved by the regu-
latory agencies, and the use of antipsychotics
in the elderly patients with dementia carries
a black box warning of increased risk of
death27,28. Yet, this analysis may be another
step towards demonstrating the acute impact
of delirium on the level of functioning, the re-
versibility of this effect by management with
antipsychotics, and warrants future studies
with a prospective design.
In summary, this analysis suggests that
delirium had an acute impact on the level of
functioning which was reversible with the
appropriate management of delirium. On the
contrary shorter delirium was associated with
functional recovery. Brain cancer, terminal
illness and hypoxia were confounders to per-
sistent delirium and functional impairment.
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